DHR · Danaher Corporation
$191.122026-05-17Sector: Healthcare; Industry: Medical - Diagnostics & Research; Sub-Industry: Life Sciences Tools & Services
Intrinsic Value Range Comparison · Mulya.ai
R&D capitalized (5yr)Base · active
$82
-57.1% vs market
Mulya.ai vs Analyst IV Comparison?
Mulya.ai IV range ($72 · $121) Analysts Range ($220 · $270) Fundamentals · historical + forward · baseitalics = DCF projection
| Period | Revenue | Rev Gr ? | Ops M% ? | Tax Rate ? | NOPAT ? | Reinvest ? | FCFF ? | WACC% ? | PV FCFF ? | ROIC ? | Inv. Cap ? | EPS ? | P/E |
|---|
| 2021.Q4 | $29.5B | — | 29.1% | 16.5% | $7.2B | −$11.1B | −$3.9B | 7.3% | — | 10.2% | $70.1B | $9.05 | — |
| 2022.Q4 | $26.6B | -9.5% | 30.1% | 12.6% | $7.0B | −$1.4B | $5.6B | 8.3% | — | 10.1% | $68.5B | $10.14 | — |
| 2023.Q4 | $23.9B | -10.3% | 23.5% | 16.8% | $4.7B | −$5.5B | −$846MM | 8.0% | — | 6.7% | $70.7B | $6.70 | — |
| 2024.Q4 | $23.9B | -0.1% | 23.1% | 16.1% | $4.6B | −$108MM | $4.5B | 8.7% | — | 6.7% | $68.3B | $5.48 | — |
| 2025.Q4 | $24.6B | 2.9% | 22.2% | 14.6% | $4.7B | $153MM | $4.8B | 8.7% | — | 6.7% | $71.1B | $5.08 | 24.9 |
| italics below = DCF projection · 10yr Rev CAGR: 4.9% |
| 2026.Q4 | $25.6B | +4.3% | 22.3% | 15.2% | $4.8B | −$288MM | $4.6B | 9.2% | $4.2B | 6.8% | $71.4B | $6.40 | 29.9 |
| 2027.Q4 | $27.1B | +5.9% | 22.7% | 15.7% | $5.2B | −$589MM | $4.6B | 9.1% | $3.9B | 7.3% | $71.9B | $6.88 | 27.8 |
| 2028.Q4 | $28.8B | +6.3% | 24.1% | 16.2% | $5.8B | −$1.2B | $4.6B | 9.0% | $3.6B | 8.0% | $73.1B | $7.70 | 24.8 |
| 2029.Q4 | $30.5B | +5.7% | 24.1% | 16.8% | $6.1B | −$616MM | $5.5B | 9.0% | $3.9B | 8.3% | $73.7B | $8.10 | 23.6 |
| 2030.Q4 | $31.9B | +4.8% | 24.1% | 17.3% | $6.4B | −$621MM | $5.8B | 8.9% | $3.7B | 8.6% | $74.4B | $8.43 | 22.7 |
|
| Term. Yr+ | $41.2B | 4.1% | 21.1% | 20.0% | $7.0B | −$3.3B | $3.6B | 8.6% | $34.5B | 8.6% | — | — | — |
Active scenario IV: $82 (-57.1% vs market)